SusanÂ M Reutzel-Edens

List of Publications by Year
in descending order

41 papers	2,618 citations	201674 27 h-index	289244 40 g-index
41 all docs	41 docs citations	41 times ranked	2711 citing authors

#	Article	IF	Citations
1	Facts and fictions about polymorphism. Chemical Society Reviews, 2015, 44, 8619-8635.	38.1	499
2	Characterization of the solid state: quantitative issues. Advanced Drug Delivery Reviews, 2001, 48, 67-90.	13.7	168
3	Crystallization and Polymorphism of Conformationally Flexible Molecules:â€‰ Problems, Patterns, and Strategies. Organic Process Research and Development, 2000, 4, 396-402.	2.7	148
4	Can computed crystal energy landscapes help understand pharmaceutical solids?. Chemical Communications, 2016, 52, 7065-7077.	4.1	146
5	Characterization of the â€œhygroscopicâ€•properties of active pharmaceutical ingredients. Journal of Pharmaceutical Sciences, 2008, 97, 1047-1059.	3.3	144
6	Anhydrates and Hydrates of Olanzapine:â€‰ Crystallization, Solid-State Characterization, and Structural Relationships. Crystal Growth and Design, 2003, 3, 897-907.	3.0	125
7	Exploring the Experimental and Computed Crystal Energy Landscape of Olanzapine. Crystal Growth and Design, 2013, 13, 1602-1617.	3.0	123
8	Assessment of the Amorphous â€œSolubilityâ€•of a Group of Diverse Drugs Using New Experimental and Theoretical Approaches. Molecular Pharmaceutics, 2015, 12, 484-495.	4.6	117
9	A Prolific Solvate Former, Galunisertib, under the Pressure of Crystal Structure Prediction, Produces Ten Diverse Polymorphs. Journal of the American Chemical Society, 2019, 141, 13887-13897.	13.7	109
10	Synthesis, Crystallization, and Biological Evaluation of an Orally Active Prodrug of Gemcitabine. Journal of Medicinal Chemistry, 2009, 52, 6958-6961.	6.4	92
11	The potential of computed crystal energy landscapes to aid solid-form development. Drug Discovery Today, 2016, 21, 912-923.	6.4	91
12	Contrasting Polymorphism of Related Small Molecule Drugs Correlated and Guided by the Computed Crystal Energy Landscape. Crystal Growth and Design, 2014, 14, 2056-2072.	3.0	72
13	Supersaturation Potential of Salt, Co-Crystal, and Amorphous Forms of a Model Weak Base. Crystal Growth and Design, 2016, 16, 737-748.	3.0	70
14	Navigating the Waters of Unconventional Crystalline Hydrates. Molecular Pharmaceutics, 2015, 12, 3069-3088.	4.6	62
15	Coamorphous Active Pharmaceutical Ingredientâ€“Small Molecule Mixtures: Considerations in the Choice of Coformers for Enhancing Dissolution and Oral Bioavailability. Journal of Pharmaceutical Sciences, 2018, 107, 5-17.	3.3	60
16	Crystal structure prediction is changing from basic science to applied technology. Faraday Discussions, 2018, 211, 459-476.	3.2	58
17	Accuracy and reproducibility in crystal structure prediction: the curious case of ROY. CrystEngComm, 2019, 21, 2080-2088.	2.6	55
18	Direct Observation of Templated Two-Step Nucleation Mechanism during Olanzapine Hydrate Formation. Crystal Growth and Design, 2017, 17, 6382-6393.	3.0	41

#	Article	IF	Citations
19	A molecular picture of the problems in ensuring structural purity of tazofelone. Journal of Molecular Structure, 2014, 1078, 26-42.	3.6	37
20	Evaluating Competing Intermolecular Interactions through Molecular Electrostatic Potentials and Hydrogen-Bond Propensities. Crystal Growth and Design, 2018, 18, 466-478.	3.0	36
21	Absorptive Dissolution Testing of Supersaturating Systems: Impact of Absorptive Sink Conditions on Solution Phase Behavior and Mass Transport. Molecular Pharmaceutics, 2017, 14, 4052-4063.	4.6	33
22	Unraveling Complexity in the Solid Form Screening of a Pharmaceutical Salt: Why so Many Forms? Why so Few?. Crystal Growth and Design, 2017, 17, 5349-5365.	3.0	33
23	Insight into Amorphous Solid Dispersion Performance by Coupled Dissolution and Membrane Mass Transfer Measurements. Molecular Pharmaceutics, 2019, 16, 448-461.	4.6	33
24	Crystal forms of LY334370 HCl: Isolation, Solidâ€State Characterization, and Physicochemical Properties. Journal of Pharmaceutical Sciences, 2003, 92, 1196-1205.	3.3	32
25	Modeling Olanzapine Solution Growth Morphologies. Crystal Growth and Design, 2018, 18, 905-911.	3.0	32
26	Inconvenient Truths about Solid Form Landscapes Revealed in the Polymorphs and Hydrates of Gandotinib. Crystal Growth and Design, 2019, 19, 2947-2962.	3.0	32
27	Origins of the unusual hygroscopicity observed in LY297802 tartrate. Journal of Pharmaceutical Sciences, 1998, 87, 1568-1571.	3.3	28
28	The unexpected discovery of the ninth polymorph of tolfenamic acid. CrystEngComm, 2021, 23, 3636-3647.	2.6	25
29	Diastereomeric Salt Resolution Based Synthesis of LY503430, an AMPA (Î±-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid) Potentiator. Organic Process Research and Development, 2005, 9, 621-628.	2.7	19
30	Influence of Drugâ€“Silica Electrostatic Interactions on Drug Release from Mesoporous Silica-Based Oral Delivery Systems. Molecular Pharmaceutics, 2020, 17, 3435-3446.	4.6	19
31	Development of a Practical Synthesis of an Aminoindanol-Derived M1 Agonist. Organic Process Research and Development, 2009, 13, 198-208.	2.7	16
32	Absorptive Dissolution Testing: An Improved Approach to Study the Impact of Residual Crystallinity on the Performance of Amorphous Formulations. Journal of Pharmaceutical Sciences, 2020, 109, 1312-1323.	3.3	15
33	A random forest model for predicting crystal packing of olanzapine solvates. CrystEngComm, 2018, 20, 3947-3950.	2.6	13
34	Crystal forms in pharmaceutical applications: olanzapine, a gift to crystal chemistry that keeps on giving. IUCrJ, 2020, 7, 955-964.	2.2	11
35	Applications of crystal structure prediction â€“ organic molecular structures: general discussion. Faraday Discussions, 2018, 211, 493-539.	3.2	8
36	Crystal structure evaluation: calculating relative stabilities and other criteria: general discussion. Faraday Discussions, 2018, 211, 325-381.	3.2	7

#	Article	IF	Citations
37	Structure searching methods: general discussion. Faraday Discussions, 2018, 211, 133-180.	3.2	3
38	Symmetry in the making. Nature Chemistry, 2020, 12, 887-888.	13.6	2
39	Crystal Morphology Modeling of Solvates and Hydrates of Organic Molecular Crystals: Olanzapine Solvate and Dihydrate. Crystal Growth and Design, 2021, 21, 4871-4877.	3.0	2
40	Diabat method for polymorph free energies: Extension to molecular crystals. Journal of Chemical Physics, 2020, 153, 244105.	3.0	1
41	Computer-aided solid form design. CrystEngComm, 0, , .	2.6	1